Re: UGT1A1*28 genotype and irinotecan-induced neutropenia: Dose matters

Journal of the National Cancer Institute

Volumn 100, Issue 3, 2008, Pages 224-225

  Ichikawa, Wataru ^a   Araki, Kazuhiro ^a   Fujita, Ken Ichi ^a   Yamamoto, Wataru ^a   Endo, Hisashi ^a   Nagashima, Fumio ^a   Tanaka, Ryuhei ^a   Miya, Toshimichi ^a   Kodama, Keiji ^a   Sunakawa, Yu ^a   Narabayashi, Masaru ^a   Ando, Yuichi ^a   Akiyama, Yuko ^a   Kawara, Kaori ^a   Sasaki, Yasutsuna ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; ANTINEOPLASTIC AGENT; BILIRUBIN URIDINE DIPHOSPHOGLUCURONOSYL TRANSFERASE 1A1; BILIRUBIN URIDINE-DIPHOSPHOGLUCURONOSYL TRANSFERASE 1A1; CAMPTOTHECIN; DRUG DERIVATIVE; GLUCURONOSYLTRANSFERASE; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; COLON CANCER; DIARRHEA; DRUG DOSE ESCALATION; DRUG INDUCED DISEASE; DRUG RESEARCH; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; JAPANESE; LETTER; LIVER METABOLISM; LUNG CANCER; NEUTROPENIA; OVARY CANCER; PHARMACOGENOMICS; PRIORITY JOURNAL; RANK SUM TEST; STATISTICAL SIGNIFICANCE; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; GENETICS; NOTE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; CAMPTOTHECIN; DOSE-RESPONSE RELATIONSHIP, DRUG; GENOTYPE; GLUCURONOSYLTRANSFERASE; HUMANS; NEUTROPENIA;

EID: 39149126731     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djm302     Document Type: Letter

References (4)

1. Hoskins JM, Goldberg RM, Qu P, Ibrahim JG, McLeod HL. UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst. 2007;99:1290-1295.
2. Sai K, Saeki M, Saito Y, et al. UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. Clin Pharmacol Ther. 2004;75:501-515.
3. Han JY, Lim HS, Shin ES, et al. Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J Clin Oncol. 2006;24:2237-2244.
4. Araki K, Fujita K, Ando Y, et al. Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer. Cancer Sci. 2006;97:1255-1259.